FIELD: biotechnology.
SUBSTANCE: invention relates to a single-domain antibody specifically bound to extracellular part of human ErbB3. Disclosed single-domain antibody contains hypervariable loops CDR1, CDR2, CDR3 with amino acid sequences SEQ ID NO: 1–3 and do not have canonical disulfide bond.
EFFECT: invention provides extending the range of single-domain antibodies specific binding to human extracellular part ErbB3.
1 cl, 4 dwg, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODIES TO DOGS' PD-1 | 2014 |
|
RU2732604C2 |
| ANTI-IL-22R-ANTIBODIES | 2017 |
|
RU2758721C2 |
| PD-L1 ANTIBODIES BINDING DOG PD-L1 | 2015 |
|
RU2722562C2 |
| SINGLE-DOMAIN ANTIBODY FOR NEUTRALIZING VIRUSES AND ITS MODIFICATION, AND A METHOD FOR THEIR USE FOR EMERGENCY PREVENTION OF DISEASES CAUSED BY INFLUENZA A VIRUS | 2021 |
|
RU2777073C1 |
| ISOLATED HUMANIZED PROTEIN BINDING TO HUMAN GLYCOPROTEIN VI, ISOLATED ANTIBODY BINDING TO HUMAN GLYCOPROTEIN VI | 2018 |
|
RU2778884C2 |
| IMMUNE CELLS EXPRESSING INVERSE UNIVERSAL CHIMERIC ANTIGEN RECEPTOR, FOR TARGETING VARIOUS MULTIPLE ANTIGENS AND METHOD FOR PRODUCTION AND USE THEREOF FOR TREATING CANCER, INFECTIONS AND AUTOIMMUNE DISEASES | 2019 |
|
RU2824391C2 |
| SINGLE-DOMAIN ANTIBODY AND ITS MODIFICATIONS THAT SPECIFICALLY BIND TO RBDS PROTEIN OF SARS-COV-2 VIRUS, AND METHOD FOR THEIR USE FOR THERAPY AND EMERGENCY PREVENTION OF DISEASES CAUSED BY SARS- COV-2 VIRUS | 2021 |
|
RU2763001C1 |
| ANTI-CANINE CTLA-4 ANTIBODY | 2020 |
|
RU2818586C2 |
| VERSIONS OF PERTUZUMAB AND THEIR ANALYTICAL CHARACTERISTICS | 2014 |
|
RU2737727C2 |
| TARGETED TGF BETA INHIBITION | 2015 |
|
RU2752424C2 |
